Welcome to the City of New Haven Economic Development
Return To City Homepage Menu is below
 
  • ONLINE SERVICES
  • FORMS
  • CALENDARS
  • EMERGENCY INFO
  • InfoNewHaven
  • Return Home
  •  
  • Economic Development Logo

    Facebook
    Twitter


    Search Department


    Get Email Updates


    Search Our Site
    transparent image for spacing

    City of New Haven Economic Development

    Growing New Haven's Economy | New Haven News

    Kolltan Pharmaceuticals Adds $5 Million to Close Series A Financing

    (8/19/2009) Kolltan closes its Series A preferred stock financing at $40 million

    NEW HAVEN, CT – August 18, 2009 - Kolltan Pharmaceuticals, Inc. announced today that it has raised an additional $5 million to close its Series A preferred stock financing at $40 million. Participants in the Series A financing, originally announced in January 2009, include Purdue Pharma, L.P., HBM BioCapital L.P., the Pritzker/Vlock family, and other substantial private life science investors.

    Kolltan is a next-generation oncology therapeutics company applying expertise in novel receptor tyrosine kinase (RTK) targets based on recent discoveries in the laboratory of Dr. Joseph Schlessinger, William H. Prusoff Professor and Chairman of the Department of Pharmacology at Yale School of Medicine. The proceeds of the Series A financing will be used to advance Kolltan's therapeutic development pipeline.

    Michael Schmertzler, Chief Executive Officer and Director of Kolltan, commented, "We are proud to announce the closing of our Series A financing and greatly appreciate the continued support of our investors. This is an exciting time for Kolltan as we continue to grow and advance our pipeline."

    About Kolltan Pharmaceuticals

    Kolltan is a development-stage company advancing therapeutics that target well-defined and validated molecular mechanisms of disease in areas of critical clinical need. Kolltan is developing a new generation of monoclonal antibody oncology therapeutics based on recent, seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at Yale School of Medicine. These proprietary discoveries elucidate novel molecular mechanisms underlying the activation of receptor tyrosine kinases, which regulate key cell processes and play a pivotal role in oncogenesis.



    Contact Name: Burns McClellan, Justin Jackson

    Contact Email: jjackson@burnsmc.com

    Contact Phone: 212-213-0006


    Follow this link for more information.


    download this document nowDocument Download

    Kolltan Pharmaceuticals, Inc. -- 300 George St, Suite 530, New Haven, CT 06511
    Click image to enlarge.
    Kolltan Pharmaceuticals, Inc. -- 300 George St, Suite 530, New Haven, CT 06511


    Return to Previous Page



    Click To Visit Department
    Click below for highlights
    Neville Wisdom
    Gateway Community College New Haven Campus
    ‘Q Bridge’ project ahead of schedule
    Footer For City Site
    Residents | Visitors | Business | Online Services | Q&A | Guide to New Haven | Government | Forms Central | Calendars | Emergency Info
    Any comments/suggestions E-mail the Webmaster for the City of New Haven or contact the Mayor's Office, 165 Church Street, New Haven CT 06510, Telephone 203-946-8200.
    New Haven City Seal